FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2975998571> ?p ?o ?g. }

• W2975998571 endingPage "34" @default.
• W2975998571 startingPage "28" @default.
• W2975998571 abstract "Twice-daily radiation concurrent with chemotherapy is one of the standard methods for limited-stage small cell lung cancer. The study was to evaluate the feasibility of chemotherapy concurrent with dose-escalating twice-daily radiotherapy by simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT) approach in patients with limited-stage small cell lung cancer.Patients with limited-stage small cell lung cancer were included, treated with twice-daily radiotherapy by SIB-IMRT concurrent with chemotherapy of etoposide plus cisplatin. Dose escalation was conducted by classical 3+3 methods with three patients enrolled in each dose level. The therapeutic gross tumor volume (GTV) was treated according to three consecutive dose levels i.e., 45 Gy at 1.5 Gy twice daily, 50 Gy at 1.67 Gy twice daily and 54 Gy at 1.8 Gy twice daily. The planning target volume (PTV) received a dose of 45 Gy delivered in 30 fractions of 1.5 Gy. The primary endpoints were acute toxicities. The secondary endpoints included overall survival (OS), progression-free survival (PFS) and loco-regional failure-free survival (LRFFS) at 1-year of follow-up.Twenty men and six women were included. The median age was 52 (30-68) months. 12 patients experienced grade 2 acute esophagitis, and 1 patient developed grade 3 acute esophagitis. Only 3 patients developed Grade 2 pneumonitis. Grade 3 or higher radiation-related pneumonia was not observed. None died of treatment-related causes. With median follow-up of 11.2 months (3.2-36.2 months), 1-year OS, PFS and LRFFS were 89.0%, 51.0% and 85.0%, respectively.Dose escalation for twice-daily radiation concurrent with chemotherapy in LS-SCLC has been safely achieved up to 54 Gy for GTV using SIB-IMRT technique.背景与目的 同步放化疗是局限期小细胞肺癌的标准治疗，但患者局部复发率和远处转移率仍较高，本研究旨在评估同步推量调强放疗治疗局限期小细胞肺癌的安全性和有效性。方法 符合局限期小细胞肺癌的患者纳入研究行同步放化疗，放疗采用每日两次方案，应用经典“3+3”模式对肿瘤大体体积（gross target volume, GTV）进行同步推量剂量递增，设定为三个剂量梯度，分别为45 Gy/30 f（单次剂量1.50 Gy）、50 Gy/30 f（单次剂量1.67 Gy）和54 Gy/30 f（单次剂量1.80 Gy）。计划靶体积均为45 Gy/30 f。主要研究终点为放疗期间及结束3个月内毒性反应。次要研究终点包括1年生存率、无进展生存期、局部无进展生存期。结果 研究共入组26例患者，中位年龄为52岁（30岁-68岁）。26例患者中，1例出现3级放射性食管炎，未观察到3级及以上放射性肺炎。中位随访时间11.2（3.2-36.2）个月，1年生存率、无进展生存率和局部无进展生存率分别为89.0%、51.0%和85.0%。结论 局限期小细胞肺癌采用化疗联合同步推量调强放疗，将GTV由45 Gy提升至54 Gy是安全有效的。." @default.
• W2975998571 created "2019-10-03" @default.
• W2975998571 creator A5003944461 @default.
• W2975998571 creator A5005038693 @default.
• W2975998571 creator A5012796164 @default.
• W2975998571 creator A5017330670 @default.
• W2975998571 creator A5027862454 @default.
• W2975998571 creator A5045326324 @default.
• W2975998571 creator A5070301751 @default.
• W2975998571 creator A5073436439 @default.
• W2975998571 creator A5074469145 @default.
• W2975998571 date "2017-01-20" @default.
• W2975998571 modified "2023-10-12" @default.
• W2975998571 title "[A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy 
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer]." @default.
• W2975998571 cites W2019607817 @default.
• W2975998571 cites W2024993508 @default.
• W2975998571 cites W2054930937 @default.
• W2975998571 cites W2056631765 @default.
• W2975998571 cites W2062410878 @default.
• W2975998571 cites W2078709072 @default.
• W2975998571 cites W2089246730 @default.
• W2975998571 cites W2093259073 @default.
• W2975998571 cites W2107403628 @default.
• W2975998571 cites W2117544940 @default.
• W2975998571 cites W2120826482 @default.
• W2975998571 cites W2141414098 @default.
• W2975998571 cites W2151906910 @default.
• W2975998571 cites W2160012348 @default.
• W2975998571 cites W2161523978 @default.
• W2975998571 cites W2163056448 @default.
• W2975998571 cites W2272984102 @default.
• W2975998571 cites W2323020638 @default.
• W2975998571 doi "https://doi.org/10.3779/j.issn.1009-3419.2017.01.04" @default.
• W2975998571 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5973293" @default.
• W2975998571 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28103970" @default.
• W2975998571 hasPublicationYear "2017" @default.
• W2975998571 type Work @default.
• W2975998571 sameAs 2975998571 @default.
• W2975998571 citedByCount "0" @default.
• W2975998571 crossrefType "journal-article" @default.
• W2975998571 hasAuthorship W2975998571A5003944461 @default.
• W2975998571 hasAuthorship W2975998571A5005038693 @default.
• W2975998571 hasAuthorship W2975998571A5012796164 @default.
• W2975998571 hasAuthorship W2975998571A5017330670 @default.
• W2975998571 hasAuthorship W2975998571A5027862454 @default.
• W2975998571 hasAuthorship W2975998571A5045326324 @default.
• W2975998571 hasAuthorship W2975998571A5070301751 @default.
• W2975998571 hasAuthorship W2975998571A5073436439 @default.
• W2975998571 hasAuthorship W2975998571A5074469145 @default.
• W2975998571 hasConcept C126322002 @default.
• W2975998571 hasConcept C143998085 @default.
• W2975998571 hasConcept C146357865 @default.
• W2975998571 hasConcept C151730666 @default.
• W2975998571 hasConcept C2776256026 @default.
• W2975998571 hasConcept C2776694085 @default.
• W2975998571 hasConcept C2777714996 @default.
• W2975998571 hasConcept C2778119113 @default.
• W2975998571 hasConcept C2779134260 @default.
• W2975998571 hasConcept C2779524853 @default.
• W2975998571 hasConcept C2779920096 @default.
• W2975998571 hasConcept C2989005 @default.
• W2975998571 hasConcept C43270747 @default.
• W2975998571 hasConcept C509974204 @default.
• W2975998571 hasConcept C71924100 @default.
• W2975998571 hasConcept C86803240 @default.
• W2975998571 hasConceptScore W2975998571C126322002 @default.
• W2975998571 hasConceptScore W2975998571C143998085 @default.
• W2975998571 hasConceptScore W2975998571C146357865 @default.
• W2975998571 hasConceptScore W2975998571C151730666 @default.
• W2975998571 hasConceptScore W2975998571C2776256026 @default.
• W2975998571 hasConceptScore W2975998571C2776694085 @default.
• W2975998571 hasConceptScore W2975998571C2777714996 @default.
• W2975998571 hasConceptScore W2975998571C2778119113 @default.
• W2975998571 hasConceptScore W2975998571C2779134260 @default.
• W2975998571 hasConceptScore W2975998571C2779524853 @default.
• W2975998571 hasConceptScore W2975998571C2779920096 @default.
• W2975998571 hasConceptScore W2975998571C2989005 @default.
• W2975998571 hasConceptScore W2975998571C43270747 @default.
• W2975998571 hasConceptScore W2975998571C509974204 @default.
• W2975998571 hasConceptScore W2975998571C71924100 @default.
• W2975998571 hasConceptScore W2975998571C86803240 @default.
• W2975998571 hasIssue "1" @default.
• W2975998571 hasLocation W29759985711 @default.
• W2975998571 hasOpenAccess W2975998571 @default.
• W2975998571 hasPrimaryLocation W29759985711 @default.
• W2975998571 hasRelatedWork W2277416945 @default.
• W2975998571 hasRelatedWork W2362771476 @default.
• W2975998571 hasRelatedWork W2366785048 @default.
• W2975998571 hasRelatedWork W2367106935 @default.
• W2975998571 hasRelatedWork W2386629326 @default.
• W2975998571 hasRelatedWork W2388458627 @default.
• W2975998571 hasRelatedWork W2407189953 @default.
• W2975998571 hasRelatedWork W2468136680 @default.
• W2975998571 hasRelatedWork W3031482208 @default.
• W2975998571 hasRelatedWork W3031855050 @default.
• W2975998571 hasVolume "20" @default.
• W2975998571 isParatext "false" @default.
• W2975998571 isRetracted "false" @default.

• next